Odmon 5mg 10pcs

Indications

Montelukast is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients

Pharmacology

Montelukast could be a specific and orally dynamic leukotriene receptor enemy that hinders the cysteinyl leukotriene receptor (CysLT1). The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are items of an arachidonic corrosive digestion system and are discharged from different cells, counting pole cells and eosinophils. Cysteinyl leukotrienes and leukotriene receptor occupation have been related to the pathophysiology of asthma & unfavorably susceptible rhinitis, counting aviation route edema, smooth muscle withdrawal, and changed cellular action related to the incendiary handle, which contributes to the signs and indications of asthma.

Dosage and Administration

Adults & adolescents (15 years & older)-

Asthma & Allergic Rhinitis: 10 mg/day

Exercise-Induced Bronchoconstriction: 10 mg/day

Pediatric patients (6 to 14 years)-

Asthma & Allergic Rhinitis: 5 mg/day

Exercise-Induced Bronchoconstriction: 5 mg/day

Pediatric patients (6 months to 5 years)-

Asthma & Allergic Rhinitis: 4 mg/day

Exercise-Induced Bronchoconstriction: Not recommended

Patients with both asthma and allergic rhinitis should take only one dose daily in the evening. For prevention of Acute prevention of Exercise-Induced Bronchoconstriction, a single dose should be taken at least 2 hours before exercise.

Interaction

Montelukast has been administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma with no appropriate increase in adverse reactions. Cytochrome P-450 inducers: Although Phenobarbital induces hepatic metabolism, no dosage adjustment for Montelukast is recommended. It is reasonable to employ appropriate clinical monitoring when potent cytochrome P-450 enzyme inducers, such as Phenobarbital or Rifampin, are co-administered with Montelukast.

Contraindication

Montelukast is contraindicated for patients with hypersensitivity to any component of this product.

Side effects

Generally, Montelukast is well-tolerated. Side effects include dizziness, headache, diarrhea, restlessness, abdominal pain, cough, fever, asthenia, rash, and upper respiratory tract infection.

Pregnancy and lactation

Pregnancy: There are no adequate and well-controlled studies of Montelukast in pregnant women. Because animal reproductive studies are not always predictive of human response, so Montelukast should be used during pregnancy only if clearly needed.

Lactation: It is not known if Montelukast is excreted in human milk, so caution should be exercised when Montelukast is given to a nursing mother.

Precautions & Warnings

Montelukast is not indicated for use in the reversal of bronchospasm in acute asthma attacks (in case of status asthmaticus). Patients with known aspirin sensitivity should continue avoidance of aspirin or other NSAIDs while taking Montelukast. In rare cases, patients on therapy with Montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with the church-Strauss syndrome, a condition that is often treated with systemic corticosteroid therapy. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and neuropathy presenting in their patients. A casual association between Montelukast and these underlying
conditions have not been established. 

Storage condition

Store in a cool and dry place, away from light. Keep all medicines out of the reach of children.